Carcinoma in situ of renal pelvis

Summary

Carcinoma in situ of renal pelvis (MONDO:0021296) is a cancer and 2 clinical trials. Top therapeutic interventions include erlotinib hydrochloride. A subtype of kidney carcinoma in situ — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	carcinoma in situ of renal pelvis
Mondo ID	MONDO:0021296
NCIT	C4597
SNOMED CT	92697000
UMLS	C0347184
MedGen	83855
Anatomy (UBERON)	UBERON:0001224
Is cancer (heuristic)	yes

Also known as: carcinoma in situ of kidney pelvis · carcinoma in situ of renal pelvis · carcinoma in situ of the kidney pelvis · carcinoma in situ of the renal pelvis · kidney pelvis carcinoma in situ · renal pelvis carcinoma in situ · renal pelvis in situ carcinoma · stage 0 renal pelvis carcinoma · stage 0is carcinoma of kidney pelvis · stage 0is carcinoma of renal pelvis · stage 0is carcinoma of the kidney pelvis · stage 0is carcinoma of the renal pelvis · stage 0is kidney pelvis carcinoma · stage 0is kidney renal pelvis urothelial cancer · stage 0is renal pelvis cancer · stage 0is renal pelvis cancer aJCC v7 · stage 0is renal pelvis urothelial carcinoma · stage 0is renal pelvis urothelial carcinoma aJCC v7

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › in situ carcinoma › kidney carcinoma in situ › carcinoma in situ of renal pelvis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00749892	PHASE2	COMPLETED	Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer
NCT04398368	PHASE2	TERMINATED	Gemcitabine for the Prevention of Intravesical Recurrence of Urothelial Cancer in Patients With Upper Urinary Tract Urothelial Cancer Undergoing Radical Nephroureterectomy, GEMINI Study

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ERLOTINIB HYDROCHLORIDE	4	1